TAKEDA PHARMACEUTICAL CO LTD
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
Takeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.
Takeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.
Over the past 7 days, alphai's AI scored 3 news stories mentioning TAK (TAKEDA PHARMACEUTICAL CO LTD). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent TAK coverage spans regulation, insider activity and financial news.
In the last 30 days, TAK insiders filed 18 SEC Form 4 transactions — no purchases and 18 sales ($10.3M). The most active reporter was Greenway Nicola Deidre Petal, Chief Human Resources Officer, with 4 filings. 6% of those filings were made under pre-arranged Rule 10b5-1 plans.
Expands Takeda's sleep‑disorder portfolio, modestly positive.
Regulatory approval unlocks market entry in Japan, expanding Takeda's revenue base and enhancing its orexin franchise.
Earnings beat may support short-term upside despite YoY decline.
Minor dilution of insider ownership; unlikely to move price.
Minor insider sell adds modest supply pressure; unlikely to move price materially.
alphai scores every news story that mentions TAK with an AI model for sentiment and relevance, and aggregates insider trades from TAKEDA PHARMACEUTICAL CO LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.
3 min readTakeda (TYO:4502/NYSE:TAK) announced Japan's approval of ORZEYFUL (oveporexton) for treating narcolepsy type 1 (NT1) in adults. The drug, discovered by Takeda, is the first to target the underlying cause of NT1. Approval follows successful Phase 3 trials showing significant symptom improvements. ORZEYFUL is also approved in China and the U.S.
2 min readTakeda Pharmaceutical reported Q1 adjusted EPS of $0.48, beating estimates by 23.08%, with sales of $7.655 billion, up 8.42% from expectations but down slightly year-over-year. The company maintained its FY2026 guidance, noting currency headwinds and pipeline advancements, including regulatory approvals for ORZEYFUL and rusfertide. Positive Phase 3 results for zasocitinib in psoriasis were also announced, with submissions planned for regulatory approval.
3 min readGreenway Nicola Deidre Petal (Chief Human Resources Officer) sold 12,980 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $18.11 ($0.24M total) on 2026-08-18.
1 min readTakeda Pharmaceutical (TAK) officer Andrew Stewart Plump plans to sell 19,651 shares, valued at $363,348.49, on or around August 19, 2026, according to a Rule 144 filing. The shares were acquired in 2020 as RSUs and PSUs.
1 min readThe FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.
4 min readTakeda Pharmaceutical (TSE:4502) received FDA approval for ORZEYFUL, a narcolepsy treatment. The stock rose 3.43% on the news, with a 31.54% total return over the past year. Analysts value the stock at ¥6,262.69, suggesting it is undervalued. Risks include generic competition and pipeline trial performance.
4 min readThe article discusses orexin receptor drugs for sleep disorders. Orexin antagonists already treat insomnia by reducing wakefulness. It focuses on orexin agonists, including Takeda’s oveporexton, which in an 8-week trial of 90 patients extended wakefulness by 12.5 to 25 minutes versus placebo and reduced cataplexy frequency by about one third, with insomnia and urinary urgency as side effects. It also notes Lilly’s orexin agonist in trials for NT1 and NT2.
7 min readKeros Therapeutics (NASDAQ:KROS) said it received a $20 million development milestone from Takeda (NYSE:TAK) after the first patient was dosed in Phase 3 ELRiSE MDS. The trial compares elritercept with epoetin alfa for anemia in low-to-intermediate-risk MDS. Keros previously got a $200 million upfront payment and may earn over $1.1 billion more milestones plus royalties, and plans to distribute 25% of the $20 million net proceeds to shareholders.
6 min readFarajallah Awny Samaan Botros (Chief Medical Officer) sold 14,006 shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $17.10 ($0.24M total) on 2026-08-10.
1 min read
%252Fhttps%253A%252F%252Ftf-cmsv2-smithsonianmag-media.s3.amazonaws.com%252Ffiler_public%252F47%252Ffc%252F47fc814d-c7fd-46ae-b4d2-5f8be614e012%252Fnarcolepsy.jpg&w=3840&q=75)
